Boehringer Ingelheim invests US$285 million investment for a new chemical Innovation Plant at Ingelheim, Germany headquarters.
The newly planned facility will focus on developing manufacturing processes for active pharmaceutical ingredients and producing drugs for clinical trial phases.
This strategic step is essential for Boehringer Ingelheim in expediting the progress of new drug candidates from their extensive research pipeline to clinical trials and eventual market approval.
By undertaking this initiative, Boehringer Ingelheim plays a pivotal role in bolstering Germany's enduring position as a prominent research and production hub, ensuring the reliable supply of medicines to patients worldwide.
The Chemical Innovation Plant bridges the gap between the smaller pilot facilities in Biberach, Germany, and Ridgefield, New Jersey, and the commercial manufacturing of active medicinal components for marketed products in Ingelheim.
The facility, which spans 11,500 square metres on seven levels, will house four production lines as well as their respective development sections. The facility was designed with future extensions in mind to accommodate changing requirements and emerging technology in mind.
The facility's operations are set to begin in 2026.